Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer

Previous studies showed that aberrant CDH1 or/and HDAC3 localization is essential for the progression of some human cancers. Here, we investigate the prognostic significance of aberrant CDH1 and HDAC3 localization in 84 pancreatic cancer patients. Our results show that increases in both membrane and cytoplasmic CDH1 correlate with lymph node metastasis (P = 0.026 and P < 0.001, respectively) and clinical stage (P = 0.020 and P < 0.001, respectively). Increased nuclear HDAC3 correlates with lymph node metastasis (P < 0.001) and advanced clinical stage (P < 0.001), but increased cytoplasmic HDAC3 does not (P > 0.05). Multivariate analysis showed that nuclear HDAC3 and cytoplasmic CDH1 (P = 0.001 and P = 0.010, respectively), as well as tumor differentiation (P = 0.009) are independent prognostic factors. Most importantly, patients with high co-expression of nuclear HDAC3 and cytoplasmic CDH1 had shorter survival times (P < 0.001), more frequent lymph node metastasis (P < 0.001), and advanced clinical stage (P < 0.001). Our studies provide convincing evidence that nuclear HDAC3 and cytoplasmic CDH1 have independent prognostic value in pancreatic cancer and provide novel targets for prognostic therapeutics.

[1]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[2]  M. Nakao,et al.  Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell – cell contacts , 1999, Oncogene.

[3]  Yan Luo,et al.  Integration of the metabolic/redox state, histone gene switching, DNA replication and S-phase progression by moonlighting metabolic enzymes , 2013, Bioscience reports.

[4]  F. Lallemand,et al.  The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells , 2015, Molecular Cancer Research.

[5]  A. Vinci,et al.  Prognostic and predictive markers in pancreatic adenocarcinoma. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  Hao Jiang,et al.  PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer. , 2014, Cancer research.

[8]  M. Huang,et al.  Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK–MMP–laminin5γ2 signaling pathway , 2015, Cancer science.

[9]  Xiaoying Lin,et al.  Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer. , 2015, American journal of cancer research.

[10]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[11]  L. Laimins,et al.  Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src , 2006, Oncogene.

[12]  C. Pilarsky,et al.  Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. , 2004, Neoplasia.

[13]  S. Wiseman,et al.  Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry , 2004, Modern Pathology.

[14]  S. Krauss,et al.  Wnt/beta-Catenin Signaling and Small Molecule Inhibitors , 2012, Current pharmaceutical design.

[15]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[16]  T. Shiozawa,et al.  Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.

[17]  F. Jiao,et al.  Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. , 2014, International journal of oncology.

[18]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[19]  A. P. Soler,et al.  Nuclear localization of E-cadherin expression in Merkel cell carcinoma. , 2000, Archives of pathology & laboratory medicine.

[20]  Nicholas C. Bauer,et al.  Mechanisms Regulating Protein Localization , 2015, Traffic.

[21]  P. Chiao,et al.  Regulation of Nuclear Translocation of HDAC3 by IκBα Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor γ Function* , 2006, Journal of Biological Chemistry.

[22]  W. Fang,et al.  Aberrant expression of nuclear vimentin and related epithelial–mesenchymal transition markers in nasopharyngeal carcinoma , 2012, International journal of cancer.

[23]  B. Barneda-Zahonero,et al.  Histone deacetylases and cancer , 2012, Molecular oncology.

[24]  S. Theocharis,et al.  Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? , 2013, World journal of gastroenterology.

[25]  Manisha Sharma,et al.  Targeting the β-catenin nuclear transport pathway in cancer. , 2014, Seminars in cancer biology.

[26]  D. Trouche,et al.  Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression , 2006, Molecular and Cellular Biology.

[27]  P. Chames,et al.  Therapeutic Antibodies for the Treatment of Pancreatic Cancer , 2010, TheScientificWorldJournal.

[28]  M. Beuran,et al.  The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[29]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[30]  N. Merchant,et al.  Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. , 2012, Frontiers in bioscience.

[31]  I. Giannopoulou,et al.  Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. , 2014, Pathology, research and practice.

[32]  Jun Yao,et al.  G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. , 2012, The Journal of clinical investigation.

[33]  J. Willis,et al.  Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer , 2000, Nature Genetics.